The company said Thursday it expects $88.4 million in proceeds after expenses and underwriting discounts. ProQR Therapeutics NV says it will use the funds from its IPO for clinical development of its lead product candidate, a therapy intended to treat cystic fibrosis, and for preclinical testing of a second drug.